A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

NCT04645147 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

NCT04773665 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

NCT07400003 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19

NCT04334980 ·Status: COMPLETED ·Phase: PHASE1

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

NCT06335849 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer

NCT01147991 ·Status: COMPLETED ·Phase: PHASE1

Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years

NCT06409494 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older

NCT07311148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

NCT05472038 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants

NCT06375512 ·Status: COMPLETED ·Phase: PHASE1

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

NCT05245838 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant

NCT05614245 ·Status: WITHDRAWN ·Phase: PHASE1

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

NCT06742281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

NCT05871541 ·Status: COMPLETED ·Phase: PHASE1

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

NCT05226390 ·Status: TERMINATED ·Phase: PHASE1

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

NCT07054099 ·Status: RECRUITING ·Phase: PHASE3

Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine

NCT04497298 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

NCT00079820 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

NCT00291889 ·Status: COMPLETED ·Phase: PHASE1

COVID-19 Booster Study in Healthy Adults in Australia

NCT05658523 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age

NCT03170609 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers

NCT05069623 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The Phase Ⅱ/Ⅲ Trial of LYB001

NCT05602558 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

NCT00561080 ·Status: COMPLETED ·Phase: PHASE3